Category: practice

The use of polygenic risk scores in clinical practice can exacerbate health disparities in ethnic and minority populations

This blog is a summary of our recent commentary on polygenic risk scores (PRS). PRS provide a rapidly emerging example of precision medicine and are based on multiple gene variants that each have weak associations with disease risks, but collectively may enhance disease predictive value in the population. The added value of PRS is unclear Read More >

Posted on by Megan C Roberts, UNC Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy; Muin J Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention; George A Mensah, Center for Translation Research and Implementation Science, National Institutes of Health, National Heart, Lung, and Blood Institute1 Comment
Categories genomics
Tags , , ,

Work in Progress: Classifying Evidence-based Genomic Applications for Practice and Prevention

applications by evidence tiers with 68 tier 1, 107 tier 2 and 7 tier 3

In our 2015 paper,“Prioritizing genomic applications for action by level of evidence: A horizon-scanning method,” we proposed a systematic scanning method that assigns genomic applications to “tiers” defined by availability of synthesized evidence. Because of the amassed evidence on the validity and utility of genomic tests and related technologies, we suggested that researchers, policy makers, Read More >

Posted on by W. David Dotson and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia
Categories evidence-based medicine, genomics
Tags , ,

Integrating Pharmacogenomics in Practice: One GIFT at a Time or a Package Deal?

a present opened with DNA capsuls spilling out of them

Testing for genetic variants related to warfarin metabolism has been the poster child for pharmacogenomics in clinical practice for over a decade. A recent publication of the Genetic Informatics Trial (GIFT) provides additional evidence for the clinical benefits of incorporating pharmacogenomics testing into the management of warfarin initiation. In this multicenter study of older individuals Read More >

Posted on by W. Gregory Feero M.D., Ph.D. Faculty, Maine-Dartmouth Family Medicine Residency Program, Augusta, Maine and Muin J. Khoury, MD, PhD, Office of Public Health Genomics, Centers for Disease Control and Prevention
Categories pharmacogenomics
Tags , ,